NCT05671393View on ClinicalTrials.gov

the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma

CompletedOBSERVATIONAL
Enrollment

801

Participants

Timeline

Start Date

January 1, 2008

Primary Completion Date

December 1, 2016

Study Completion Date

December 15, 2022

Conditions
Gastric Neuroendocrine Carcinoma
Trial Locations (1)

350001

Chang-ming Huang, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT05671393 - the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter